

V.A. CENTER
BONHAM, TEXAS

March 22, 1972

PHARMACY AND THERAPEUTICS COMMITTEE, RCS: 10-190

1. The March meeting of the Pharmacy and Therapeutics Committee was called to order at 3:30 p.m. with the following members present:

Dr. N. Chick, Chairman	Dr. E. C. Williams, Member
Dr. H. B. Griffin, Member	Dr. Patrick Kelly, Member
Dr. R. Mesina, Member	Dr. John Durst, Member
Dr. J. L. Stevens, Member	John McKinzie, Secretary
Dr. R. W. Gaylord, Member	

2. New drug(s):

a. GAVISCON TABLETS-Marion. Dr. Sidoti and Dr. Mesina requested this drug for selected patients requiring action other than that of ordinary antacids. Gaviscon forms a viscous gel-like barrier of floating foam in the cardia and fundus of the stomach. It is purported to be a specific treatment for heartburn accompanying hiatal hernia. The Committee approved the stocking of limited quantities of the drug since it will not be used as a "routine" antacid.

b. PROMETHAZINE 25 mg. TABLETS and PROMETHAZINE INJECTION 25 mg/cc. (Phenergan-Wyeth). Phenergan tablets and the injectable forms were requested by Dr. Gaylord. Phenergan has many accepted uses. Most notable are: (1) As a sedative, (2) in the management of allergic conditions, (3) in the control of cough, both to diminish the cough reflex and promote expectoration, and (4) in the management of nausea and vomiting. Dr. Gaylord expressed the most interest in Phenergan's anti-nausea effect. Cost of the drug would be a factor in prescribing the drug for its antihistaminic effect. The Committee agreed to the stocking of both dosage forms and placing them in the formulary.

c. SODIUM TYROPAANOATE (Bilopaque-Winthrop). Bilopaque, 750 mg. capsules was requested by the Chairman for use as a roentgenographic contrast medium in cholecystography. The drug's radiopaque metabolites, when concentrated in the gallbladder, allow delineation of the gallbladder and possible visualization of the extrahepatic ducts. The Chairman stated that he felt this drug was superior to the one presently used and that excellent results had been obtained with the use of a trial supply. Bilopaque will be stocked and placed in the formulary.

3. Drug(s) delisted: SODIUM IPODATE 500 mg. CAPSULES (Oragrafin Sodium-Squibb). This drug will be delisted and replaced with Bilopaque. All existing stocks will either be used or returned to the manufacturer for credit.